Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Netherlands, and Spain: an interrupted time series analysis
- PMID: 37663263
- PMCID: PMC10469888
- DOI: 10.3389/fphar.2023.1207976
Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Netherlands, and Spain: an interrupted time series analysis
Abstract
Background: In March 2018, the European pregnancy prevention programme for oral retinoids was updated as part of risk minimisation measures (RMM), emphasising their contraindication in pregnant women. Objective: To measure the impact of the 2018 revision of the RMMs in Europe by assessing the utilisation patterns of isotretinoin, alitretinoin and acitretin, contraceptive measures, pregnancy testing, discontinuation, and pregnancy occurrence concomitantly with a retinoid prescription. Methods: An interrupted time series (ITS) analysis to compare level and trend changes after the risk minimisation measures implementation was conducted on a cohort of females of childbearing age (12-55 years of age) from January 2010 to December 2020, derived from six electronic health data sources in four countries: Denmark, Netherlands, Spain, and Italy. Monthly utilisation figures (incidence rates [IR], prevalence rates [PR] and proportions) of oral retinoids were calculated, as well as discontinuation rates, contraception coverage, pregnancy testing, and rates of exposed pregnancies to oral retinoids, before and after the 2018 RMMs. Results: From 10,714,182 females of child-bearing age, 88,992 used an oral retinoid at any point during the study period (mean age 18.9-22.2 years old). We found non-significant level and trend changes in incidence or prevalence of retinoid use in females of child-bearing age after the 2018 RMMs. The reason of discontinuation was unknown in >95% of cases. Contraception use showed a significant increase trend in Spain; for other databases this information was limited. Pregnancy testing was hardly recorded thus was not possible to model ITS analyses. After the 2018 RMM, rates of pregnancy occurrence during retinoid use, and start of a retinoid during a pregnancy varied from 0.0 to 0.4, and from 0.2 to 0.8, respectively. Conclusion: This study shows a limited impact of the 2018 RMMs on oral retinoids utilisation patterns among females of child-bearing age in four European countries. Pregnancies still occur during retinoid use, and oral retinoids are still prescribed to pregnant women. Contraception and pregnancy testing information was limited in most databases. Regulators, policymakers, prescribers, and researchers must rethink implementation strategies to avoid any pregnancy becoming temporarily related to retinoid use.
Keywords: acne; contraceptive measures; dermatologic conditions; isotretinoin; oral retinoids; pregnancy prevention programme; risk minimisation measures.
Copyright © 2023 Durán, Riera-Arnau, Abtahi, Pajouheshnia, Hoxhaj, Gamba, Alsina, Martin-Perez, Garcia-Poza, Llorente-Garcia, Gonzalez-Bermejo, Ibánez, Sabaté, Vidal, Ballarín, Sanfélix-Gimeno, Rodríguez-Bernal, Peiró, García-Sempere, Sanchez-Saez, Ientile, Ingrasciotta, Guarneri, Tanaglia, Tari, Herings, Houben, Swart-Polinder, Holthuis, Huerta, Gini, Roberto, Bartolini, Paoletti, Limoncella, Girardi, Hyeraci, Andersen, Kristiansen, Hallgreen, Klungel and Sturkenboom.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures



Similar articles
-
Impact of 2018 EU Risk Minimisation Measures and Revised Pregnancy Prevention Programme on Utilisation and Prescribing Trends of Medicinal Products Containing Valproate: An Interrupted Time Series Study.Drug Saf. 2023 Jul;46(7):689-702. doi: 10.1007/s40264-023-01314-3. Epub 2023 Jun 9. Drug Saf. 2023. PMID: 37294532 Free PMC article.
-
The implementation of risk minimization measures to prevent teratogenic pregnancy outcomes related to oral retinoid and valproate use in Belgium.Acta Clin Belg. 2022 Oct;77(5):815-822. doi: 10.1080/17843286.2021.1983708. Epub 2021 Sep 26. Acta Clin Belg. 2022. PMID: 34569444
-
Prescription retinoid and contraception use in women in Australia: A population-based study.Australas J Dermatol. 2024 Aug;65(5):428-436. doi: 10.1111/ajd.14294. Epub 2024 May 1. Australas J Dermatol. 2024. PMID: 38693687
-
Alitretinoin as a Treatment Modality for Ichthyosis in Women of Childbearing Age: A Case Series and Review of the Literature.Dermatology. 2024;240(1):170-177. doi: 10.1159/000533934. Epub 2023 Sep 4. Dermatology. 2024. PMID: 37666225 Review.
-
Current use and future potential role of retinoids in dermatology.Drugs. 1997 Mar;53(3):358-88. doi: 10.2165/00003495-199753030-00003. Drugs. 1997. PMID: 9074840 Review.
Cited by
-
Latvian Healthcare Professionals' Self-Reported Knowledge, Attitudes, and Behaviors Related to Pregnancy Prevention Program Materials for Valproate-Containing Medicines.Pharmacy (Basel). 2024 Dec 4;12(6):182. doi: 10.3390/pharmacy12060182. Pharmacy (Basel). 2024. PMID: 39728847 Free PMC article.
-
Adverse Pregnancy and Child Outcomes in Oral Retinoid-Exposed Pregnancies: A Nationwide Population-Based Study.J Korean Med Sci. 2024 Jul 8;39(26):e201. doi: 10.3346/jkms.2024.39.e201. J Korean Med Sci. 2024. PMID: 38978488 Free PMC article.
-
Compliance with the European Pregnancy Prevention Programme in Isotretinoin Treatment: Safety Outcomes and Dose-Related Correlations.J Clin Med. 2025 May 16;14(10):3497. doi: 10.3390/jcm14103497. J Clin Med. 2025. PMID: 40429495 Free PMC article.
References
-
- Crijns H. J., van Rein N., Gispen-de Wied C. C., Straus S. M., de Jong-van den Berg L. T. (2012). Prescriptive contraceptive use among isotretinoin users in The Netherlands in comparison with non-users: A drug utilisation study. Pharmacoepidemiol Drug Saf. 21, 1060–1066. 10.1002/pds.3200 - DOI - PubMed
-
- Crijns I., Mantel-Teeuwisse A., Bloemberg R., Pinas E., Straus S., de Jong-van den Berg L. (2013). Healthcare professional surveys to investigate the implementation of the isotretinoin pregnancy prevention programme: A descriptive study. Expert Opin. Drug Saf. 12 (1), 29–38. 10.1517/14740338.2013.745850 - DOI - PubMed
LinkOut - more resources
Full Text Sources
Research Materials